ZLD.AX - Zelira Therapeutics Limited

ASX - ASX Delayed price. Currency in AUD
Currency in AUD

Valuation measures4

Market cap (intra-day) 18.38M
Enterprise value 18.74M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)17.40
Price/book (mrq)0.57
Enterprise value/revenue 21.06
Enterprise value/EBITDA -1.90

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 340.87%
S&P500 52-week change 34.08%
52-week high 35.0000
52-week low 30.9000
50-day moving average 31.0598
200-day moving average 31.1348

Share statistics

Avg vol (3-month) 333.37k
Avg vol (10-day) 3182.11k
Shares outstanding 511.35M
Implied shares outstanding 6N/A
Float 86.63M
% held by insiders 137.36%
% held by institutions 10.00%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:175
Last split date 314 Apr 2022

Financial highlights

Fiscal year

Fiscal year ends 30 June 2022
Most-recent quarter (mrq)31 Dec 2022


Profit margin 0.00%
Operating margin (ttm)-1,269.16%

Management effectiveness

Return on assets (ttm)-18.37%
Return on equity (ttm)-28.72%

Income statement

Revenue (ttm)889.87k
Revenue per share (ttm)0.09
Quarterly revenue growth (yoy)-89.40%
Gross profit (ttm)601.57k
EBITDA -10.93M
Net income avi to common (ttm)-9.96M
Diluted EPS (ttm)-0.9800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)133.79k
Total cash per share (mrq)0.01
Total debt (mrq)494.19k
Total debt/equity (mrq)1.53
Current ratio (mrq)1.16
Book value per share (mrq)3.36

Cash flow statement

Operating cash flow (ttm)-8.41M
Levered free cash flow (ttm)-4.24M